Phathom Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 7, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 7, 2024
PHAT$5.33+1.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(in thousands)
| Years EndedDecember 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows from operating activities | ||
| Net loss | $(201,592) | $(197,723) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 575 | 620 |
| Stock-based compensation | 45,025 | 24,133 |
| Issuance of PIK interest debt | 3,583 | 3,484 |
| Accrued interest on revenue interest financing liability | 24,727 | 14,079 |
| Amortization of debt discount | 1,877 | 2,110 |
| Other | 1,869 | 1,329 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (8,067) | (1,860) |
| Accounts receivable, net | (1,637) | — |
| Accounts payable and accrued expenses (includes changes in related party amounts of $184 and $1,139, respectively) | 6,410 | 8,679 |
| Accrued clinical trial expenses | — | (1,402) |
| Accrued interest | 292 | 377 |
| Operating right-of-use assets and lease liabilities | 194 | (238) |
| Inventory | (9,442) | — |
| Other long-term assets | (1,394) | (118) |
| Net cash used in operating activities | (137,580) | (146,530) |
| Cash flows from investing activities | ||
| Cash paid for property, plant and equipment | (1,634) | (1,041) |
| Net cash used in investing activities | (1,634) | (1,041) |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock from exercise of stock options | 124 | — |
| Net proceeds from issuance of debt | 39,318 | — |
| Net proceeds from underwritten public offering | 141,390 | — |
| Net proceeds from revenue interest financing transaction | 172,675 | 95,446 |
| Net proceeds from issuance of common stock under ATM facility | 14,073 | 24,596 |
| Net cash provided by financing activities | 367,580 | 120,042 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | 228,366 | (27,529) |
| Cash and cash equivalents and restricted cash – beginning of period | 155,890 | 183,419 |
| Cash and cash equivalents and restricted cash – end of period | $384,256 | $155,890 |
| Supplemental disclosure of cash flow information | ||
| Interest paid | $11,133 | $7,033 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Property and equipment purchases included in accounts payable and accrued expenses | $18 | $138 |
| Final interest payment fee | $2,200 | $— |
| Settlement of ESPP liability in common stock | $1,417 | $909 |
| Settlement of 401(k) liability in common stock | $1,612 | $1,116 |
| Operating lease liabilities arising from obtaining right-of-use assets | $— | $554 |
See accompanying notes.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.